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Hepatocellular carcinoma (HCC) develops in an environ-
ment of chronic inflammation. Curative treatments are
plagued by frequent recurrences locally near the treated
tumor, regionally within the inflamed liver, and systemi-
cally, and yet no adjuvant therapies are known to prevent
recurrence. Here the efficacy of immunotherapy with
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stereotactic radiation (SBRT) in an immune-competent
murine model is evaluated. A syngeneic HCC cell line
(Hep 55.1c) is injected into the liver of C57BL/6 mice
using ultrasound guidance. The tumors are measured and
treated using computed tomography and a single dose of
intravenous contrast that is taken up by resident liver
macrophages allowing visualization of tumors for at least
30 days. Stereotactic radiation is delivered using a Small
Animal Radiation Research Platform. Three doses of
250 ug anti-Programmed Cell Death-1 antibody (aPD-1)
are delivered concurrently with 30 Gy SBRT in 3 fractions.
This combination reduces the growth rate of tumors and
improves survival (p < 0.05). Addition of aPD-1 to SBRT
is associated with increases in CD8+ cytotoxic T cells
based on flow cytometry (Figure 1a) and CD3+ T cells
based on six-color immunofluorescence, and this augmen-
tation of immune response is associated with increased
ICOS expression on T cells within tumor and spleen.
Importantly, the tumors grow out rapidly after aPD-1 is
discontinued. The percentage of regulatory T cells (CD4
+CD25+FOXP3+) also increases significantly after aPD-1
alone and in combination with SBRT (p < 0.001), suggest-
ing a potential mechanism by which cytotoxic T cells
could be rendered anergic. In addition, the combination of
aPD-1 plus SBRT induced programmed cell death-1
ligand expression on suppressive macrophages based on
flow cytometry (Figure 1b) and immunofluorescence, sug-
gesting another potential mechanism of resistance to long
term immune control of the tumors. Conclusion: Tumor
response to SBRT can be augmented by concurrent
administration of aPD-1 antibody. The efficacy of this
combination therapy is transient, however. The environ-
ment of chronic immune suppression in most patients
affected by HCC adds to the rationale of this immune-
radiotherapy combination, but the mechanisms of
immune resistance will need to be overcome for this
combination to generate lasting immunity.
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